{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:08:25Z","timestamp":1793920105056,"version":"4.8.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T00:00:00Z","timestamp":1610755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T00:00:00Z","timestamp":1610755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006209","name":"Radboud University Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s40265-020-01448-z","type":"journal-article","created":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T11:02:36Z","timestamp":1610794956000},"page":"349-366","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8625-034X","authenticated-orcid":false,"given":"C. A. J.","family":"Michielsens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7934-3329","authenticated-orcid":false,"given":"M. E.","family":"van Muijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9740-5607","authenticated-orcid":false,"given":"L. M.","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-2673","authenticated-orcid":false,"given":"J. M. P. A.","family":"van den Reek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3872-5704","authenticated-orcid":false,"given":"E. M. G. J","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,16]]},"reference":[{"issue":"5","key":"1448_CR1","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826\u201350. https:\/\/doi.org\/10.1016\/j.jaad.2008.02.039.","journal-title":"J Am Acad Dermatol."},{"key":"1448_CR2","unstructured":"Zorginstituut Nederland. https:\/\/www.medicijnkosten.nl\/. Accessed 24 Sep 2020."},{"issue":"2","key":"1448_CR3","doi-asserted-by":"publisher","first-page":"e12817","DOI":"10.1111\/dth.12817","volume":"32","author":"E Thomaidou","year":"2019","unstructured":"Thomaidou E, Ramot Y. Injection site reactions with the use of biological agents. Dermatol Ther. 2019;32(2):e12817. https:\/\/doi.org\/10.1111\/dth.12817.","journal-title":"Dermatol Ther."},{"issue":"6","key":"1448_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1610-0387.2010.07339.x","volume":"8","author":"K Scherer","year":"2010","unstructured":"Scherer K, Spoerl D, Bircher AJ. Adverse drug reactions to biologics. J Dtsch Dermatol Ges. 2010;8(6):411\u201326. https:\/\/doi.org\/10.1111\/j.1610-0387.2010.07339.x.","journal-title":"J Dtsch Dermatol Ges."},{"issue":"6","key":"1448_CR5","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1111\/bjd.13539","volume":"172","author":"P Gisondi","year":"2015","unstructured":"Gisondi P, Cazzaniga S, Chimenti S, Maccarone M, Picardo M, Girolomoni G, et al. Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry. Br J Dermatol. 2015;172(6):1613\u201320. https:\/\/doi.org\/10.1111\/bjd.13539.","journal-title":"Br J Dermatol."},{"issue":"1","key":"1448_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jaad.2017.01.037","volume":"77","author":"I Snast","year":"2017","unstructured":"Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017;77(1):88-97e5. https:\/\/doi.org\/10.1016\/j.jaad.2017.01.037.","journal-title":"J Am Acad Dermatol."},{"issue":"10","key":"1448_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00403-015-1593-8","volume":"307","author":"K Reich","year":"2015","unstructured":"Reich K, Mrowietz U, Radtke MA, Thaci D, Rustenbach SJ, Spehr C, et al. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015;307(10):875\u201383. https:\/\/doi.org\/10.1007\/s00403-015-1593-8.","journal-title":"Arch Dermatol Res."},{"issue":"6","key":"1448_CR8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685\u201399. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655.","journal-title":"Ann Rheum Dis."},{"key":"1448_CR9","unstructured":"FDA. Highlights of prescribing information (Alefacept). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125036s0144lbl.pdf. Accessed 24 Sept 2020."},{"issue":"3","key":"1448_CR10","first-page":"411","volume":"3","author":"C Jenneck","year":"2007","unstructured":"Jenneck C, Novak N. The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis. Ther Clin Risk Manag. 2007;3(3):411\u201320.","journal-title":"Ther Clin Risk Manag."},{"issue":"1","key":"1448_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","volume":"18","author":"Z Munn","year":"2018","unstructured":"Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143. https:\/\/doi.org\/10.1186\/s12874-018-0611-x.","journal-title":"BMC Med Res Methodol."},{"key":"1448_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4897","author":"S Atalay","year":"2020","unstructured":"Atalay S, van den Reek J, den Broeder AA, van Vugt LJ, Otero ME, Njoo MD, et al. Comparison of tightly controlled dose reduction of biologics with usual care for patients with psoriasis: a randomized clinical trial. JAMA Dermatol. 2020. https:\/\/doi.org\/10.1001\/jamadermatol.2019.4897.","journal-title":"JAMA Dermatol."},{"issue":"6","key":"1448_CR13","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1111\/bjd.15722","volume":"177","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Ferris LK, Yamauchi PS, Qureshi A, Leonardi CL, Farahi K, et al. Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR). Br J Dermatol. 2017;177(6):1552\u201361. https:\/\/doi.org\/10.1111\/bjd.15722.","journal-title":"Br J Dermatol."},{"issue":"14","key":"1448_CR14","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1503824.","journal-title":"N Engl J Med."},{"key":"1448_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18143","author":"K Reich","year":"2019","unstructured":"Reich K, Puig L, Szepietowski JC, Paul C, Lacour JP, Tsianakas A, et al. Secukinumab dosing optimization in patients with moderate to severe plaque psoriasis: results from the randomised, open-label OPTIMISE study. Br J Dermatol. 2019. https:\/\/doi.org\/10.1111\/bjd.18143.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1448_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/ftd.0000000000000420","volume":"39","author":"JS van Bezooijen","year":"2017","unstructured":"van Bezooijen JS, van Doorn MBA, Schreurs MWJ, Koch BCP, Te Velthuis H, Prens EP, et al. Prolongation of biologic dosing intervals in patients with stable psoriasis: a feasibility study. Ther Drug Monit. 2017;39(4):379\u201386. https:\/\/doi.org\/10.1097\/ftd.0000000000000420.","journal-title":"Ther Drug Monit."},{"key":"1448_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16256","author":"MC Ovejero-Benito","year":"2020","unstructured":"Ovejero-Benito MC, Munoz-Aceituno E, Sabador D, Reolid A, Llamas-Velasco M, Prieto-Perez R, et al. Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2020. https:\/\/doi.org\/10.1111\/jdv.16256.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"11","key":"1448_CR18","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1111\/j.1468-3083.2012.04610.x","volume":"27","author":"T Taniguchi","year":"2013","unstructured":"Taniguchi T, Noda S, Takahashi N, Yoshimura H, Mizuno K, Adachi M. An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment. J Eur Acad Dermatol Venereol. 2013;27(11):1444\u20137. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04610.x.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"7","key":"1448_CR19","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ad.2015.02.003","volume":"106","author":"O Baniandres","year":"2015","unstructured":"Baniandres O, Rodriguez-Soria VJ, Romero-Jimenez RM, Suarez R. Dose modification in biologic therapy for moderate to severe psoriasis: a descriptive analysis in a clinical practice setting. Actas Dermosifiliogr. 2015;106(7):569\u201377. https:\/\/doi.org\/10.1016\/j.ad.2015.02.003.","journal-title":"Actas Dermosifiliogr."},{"issue":"12","key":"1448_CR20","first-page":"1584","volume":"15","author":"F Bardazzi","year":"2016","unstructured":"Bardazzi F, Loi C, Prignano F, Ricceri F, Giordano F, Patrizi A, et al. Down-titration of infliximab: the real-life use in psoriatic patients. J Drugs Dermatol. 2016;15(12):1584\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"1448_CR21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3109\/09546634.2015.1034070","volume":"26","author":"JM Carrascosa","year":"2015","unstructured":"Carrascosa JM, Garcia-Doval I, Perez-Zafrilla B, Carretero G, Vanaclocha F, Dauden E, et al. Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: a cross-sectional study in clinical practice. J Dermatolog Treat. 2015;26(6):502\u20136. https:\/\/doi.org\/10.3109\/09546634.2015.1034070.","journal-title":"J Dermatolog Treat."},{"issue":"5","key":"1448_CR22","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/jdv.14145","volume":"31","author":"M Esposito","year":"2017","unstructured":"Esposito M, Gisondi P, Conti A, Giunta A, Del Giglio M, Di Mercurio M, et al. Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. J Eur Acad Dermatol Venereol. 2017;31(5):863\u20139. https:\/\/doi.org\/10.1111\/jdv.14145.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"10","key":"1448_CR23","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/j.1468-3083.2011.04290.x","volume":"26","author":"C Fotiadou","year":"2012","unstructured":"Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre. J Eur Acad Dermatol Venereol. 2012;26(10):1298\u2013303. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04290.x.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"3","key":"1448_CR24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2340\/00015555-2571","volume":"97","author":"K Hansel","year":"2017","unstructured":"Hansel K, Bianchi L, Lanza F, Bini V, Stingeni L. Adalimumab dose tapering in psoriasis: predictive factors for maintenance of complete clearance. Acta Derm Venereol. 2017;97(3):346\u201350. https:\/\/doi.org\/10.2340\/00015555-2571.","journal-title":"Acta Derm Venereol."},{"issue":"7","key":"1448_CR25","doi-asserted-by":"publisher","first-page":"e292","DOI":"10.1111\/jdv.14826","volume":"32","author":"EB Lee","year":"2018","unstructured":"Lee EB, Thomas LW, Egeberg A, Wu JJ. Dosage adjustments in patients with psoriasis on adalimumab\u2014a retrospective chart review. J Eur Acad Dermatol Venereol. 2018;32(7):e292\u20133. https:\/\/doi.org\/10.1111\/jdv.14826.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"5","key":"1448_CR26","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/bjd.12543","volume":"169","author":"A L\u00f3pez-Ferrer","year":"2013","unstructured":"L\u00f3pez-Ferrer A, Vilarrasa E, Gich IJ, Puig L. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. Br J Dermatol. 2013;169(5):1141\u20137. https:\/\/doi.org\/10.1111\/bjd.12543.","journal-title":"Br J Dermatol."},{"issue":"2","key":"1448_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2340\/00015555-2209","volume":"96","author":"S Piaserico","year":"2016","unstructured":"Piaserico S, Gisondi P, De Simone C, Marinello E, Conti A, Amerio P, et al. Down-titration of adalimumab and etanercept in psoriatic patients: a multicentre observational study. Acta Derm Venereol. 2016;96(2):251\u20132. https:\/\/doi.org\/10.2340\/00015555-2209.","journal-title":"Acta Derm Venereol."},{"issue":"3","key":"1448_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1684\/ejd.2013.2017","volume":"23","author":"L Puig","year":"2013","unstructured":"Puig L, Morales-M\u00fanera CE. Implementing therapeutic goals in maintenance treatment of psoriasis with biologics: adalimumab can be more cost-effective than infliximab or ustekinumab in real life. Eur J Dermatol. 2013;23(3):407\u20138. https:\/\/doi.org\/10.1684\/ejd.2013.2017.","journal-title":"Eur J Dermatol."},{"issue":"3","key":"1448_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3109\/09546634.2015.1088127","volume":"27","author":"RM Romero-Jimenez","year":"2016","unstructured":"Romero-Jimenez RM, Escudero-Vilaplana V, Baniandres Rodriguez O, Garcia-Gonzalez X, Sanjurjo SM. Efficiency of biological therapies in patients with moderate to severe psoriasis: impact of a pharmacotherapeutic protocol. J Dermatolog Treat. 2016;27(3):198\u2013202. https:\/\/doi.org\/10.3109\/09546634.2015.1088127.","journal-title":"J Dermatolog Treat."},{"issue":"8","key":"1448_CR30","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1080\/09546634.2018.1466978","volume":"29","author":"RM Romero-Jimenez","year":"2018","unstructured":"Romero-Jimenez RM, Escudero-Vilaplana V, Baniandres Rodriguez O, Garcia Martin E, Mateos Mayo A, Sanjurjo SM. Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2018;29(8):792\u20136. https:\/\/doi.org\/10.1080\/09546634.2018.1466978.","journal-title":"J Dermatolog Treat."},{"key":"1448_CR31","doi-asserted-by":"publisher","unstructured":"Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl 2):ii65\u201368; discussion ii9-73. https:\/\/doi.org\/10.1136\/ard.2004.031237.","DOI":"10.1136\/ard.2004.031237"},{"issue":"4","key":"1448_CR32","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/09546634.2017.1395794","volume":"29","author":"G Carretero","year":"2018","unstructured":"Carretero G, Puig L, Carrascosa JM, Ferrandiz L, Ruiz-Villaverde R, de la Cueva P, et al. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. J Dermatolog Treat. 2018;29(4):334\u201346. https:\/\/doi.org\/10.1080\/09546634.2017.1395794.","journal-title":"J Dermatolog Treat."},{"issue":"11","key":"1448_CR33","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1093\/rheumatology\/key205","volume":"57","author":"LM Verhoef","year":"2018","unstructured":"Verhoef LM, Selten EMH, Vriezekolk JE, de Jong AJL, van den Hoogen FHJ, den Broeder AA, et al. The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study. Rheumatology (Oxford). 2018;57(11):1947\u201355. https:\/\/doi.org\/10.1093\/rheumatology\/key205.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1448_CR34","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210715.","journal-title":"Ann Rheum Dis."},{"issue":"16","key":"1448_CR35","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40265-018-0994-3","volume":"78","author":"W Ye","year":"2018","unstructured":"Ye W, Tucker LJ, Coates LC. Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity. Drugs. 2018;78(16):1705\u201315. https:\/\/doi.org\/10.1007\/s40265-018-0994-3.","journal-title":"Drugs."},{"issue":"2","key":"1448_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/bjd.12654","volume":"170","author":"L Hsu","year":"2014","unstructured":"Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170(2):261\u201373. https:\/\/doi.org\/10.1111\/bjd.12654.","journal-title":"Br J Dermatol."},{"issue":"4","key":"1448_CR37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299\u2013316. https:\/\/doi.org\/10.1007\/s40259-017-0231-8.","journal-title":"BioDrugs."},{"issue":"6","key":"1448_CR38","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/bjd.12404","volume":"168","author":"K Reich","year":"2013","unstructured":"Reich K, Wozel G, Zheng H, van Hoogstraten HJ, Flint L, Barker J. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol. 2013;168(6):1325\u201334. https:\/\/doi.org\/10.1111\/bjd.12404.","journal-title":"Br J Dermatol."},{"key":"1448_CR39","unstructured":"Higgins. JPT. Methodological Expectations of Cochrane Intervention Reviews. Cochrane, London. 2019. https:\/\/community.cochrane.org\/sites\/default\/files\/uploads\/inline-files\/MECIR%20October%202019%20Final%20Online%20version.pdf. Accessed 24 Sep 2020."},{"issue":"8","key":"1448_CR40","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1346-8138.2008.00508.x","volume":"35","author":"JI Na","year":"2008","unstructured":"Na JI, Kim JH, Park KC, Youn SW. Low-dose etanercept therapy in moderate to severe psoriasis in Korean. J Dermatol. 2008;35(8):484\u201390. https:\/\/doi.org\/10.1111\/j.1346-8138.2008.00508.x.","journal-title":"J Dermatol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01448-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-020-01448-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01448-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T05:37:41Z","timestamp":1615441061000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-020-01448-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,16]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1448"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01448-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,16]]},"assertion":[{"value":"16 January 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"C. A. J. Michielsens has nothing to disclose. M. E. van Muijen carries out clinical trials for Abbvie, Celgene, Janssen, and Novartis, and has received a speaking fee from Janssen. All funding is not personal but goes to the independent Research Fund of the Department of Dermatology of the Radboud University Medical Center, Nijmegen (Radboudumc), the Netherlands. L. M. Verhoef has nothing to disclose. J. M. P.A. van den Reek has carried out clinical trials for AbbVie, Celgene, and Janssen, and has received speaking fees from\/attended advisory boards for AbbVie, Janssen, BMS, and Eli Lilly, and reimbursement for attending a symposium from Janssen, Pfizer, Celgene, and AbbVie. All funding is not personal but goes to the independent research fund of the Department of Dermatology of Radboud University Medical Center, Nijmegen, the Netherlands. E. M. G. J. de Jong has received research grants for the independent research fund of the Department of Dermatology of the Radboud University Medical Center, Nijmegen, the Netherlands, from AbbVie, Novartis, Janssen Pharmaceutica, and Leo Pharma. Has acted as a consultant and\/or paid speaker for and\/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis including AbbVie, Janssen Pharmaceutica, Novartis, Lily, Celgene, Leo Pharma, UCB, and Almirall. All funding is not personal but goes to the independent research fund of the Department of Dermatology of Radboud University Medical Center Nijmegen, the Netherlands.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing is not applicable, since no datasets were generated or analyzed for the generation of the current article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable\u2014this article is based on previously performed studies and does not include any new studies on humans or animals conducted by any of the authors.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this article and take responsibility for the integrity of the work. All authors read and approved the publication of the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}